Toll Free: 1-888-928-9744
Published: Apr, 2014 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
RedHill Biopharma Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'RedHill Biopharma Ltd. - Product Pipeline Review - 2014', provides an overview of the RedHill Biopharma Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of RedHill Biopharma Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of RedHill Biopharma Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of RedHill Biopharma Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the RedHill Biopharma Ltd.'s pipeline products Reasons to buy - Evaluate RedHill Biopharma Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of RedHill Biopharma Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the RedHill Biopharma Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of RedHill Biopharma Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of RedHill Biopharma Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of RedHill Biopharma Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 RedHill Biopharma Ltd. Snapshot 5 RedHill Biopharma Ltd. Overview 5 Key Information 5 Key Facts 5 RedHill Biopharma Ltd. - Research and Development Overview 6 Key Therapeutic Areas 6 RedHill Biopharma Ltd. - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Combination Treatment Modalities 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 RedHill Biopharma Ltd. - Pipeline Products Glance 15 RedHill Biopharma Ltd. - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 RedHill Biopharma Ltd. - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 RedHill Biopharma Ltd. - Early Stage Pipeline Products 17 Preclinical Products/Combination Treatment Modalities 17 RedHill Biopharma Ltd. - Drug Profiles 18 (rifabutin + amoxicillin sodium + omeprazole) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 (rifabutin + clarithromycin + clofazimine) 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 carvedilol CR 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 ondansetron hydrochloride CR 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 RedHill Biopharma Ltd. - Pipeline Analysis 25 RedHill Biopharma Ltd. - Pipeline Products by Target 25 RedHill Biopharma Ltd. - Pipeline Products by Route of Administration 27 RedHill Biopharma Ltd. - Pipeline Products by Molecule Type 28 RedHill Biopharma Ltd. - Pipeline Products by Mechanism of Action 29 RedHill Biopharma Ltd. - Recent Pipeline Updates 31 RedHill Biopharma Ltd. - Locations And Subsidiaries 39 Head Office 39 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 41 Disclaimer 41
List of Tables RedHill Biopharma Ltd., Key Information 5 RedHill Biopharma Ltd., Key Facts 5 RedHill Biopharma Ltd. - Pipeline by Indication, 2014 7 RedHill Biopharma Ltd. - Pipeline by Stage of Development, 2014 8 RedHill Biopharma Ltd. - Monotherapy Products in Pipeline, 2014 9 RedHill Biopharma Ltd. - Combination Treatment Modalities in Pipeline, 2014 10 RedHill Biopharma Ltd. - Partnered Products in Pipeline, 2014 11 RedHill Biopharma Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12 RedHill Biopharma Ltd. - Out-Licensed Products in Pipeline, 2014 13 RedHill Biopharma Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 14 RedHill Biopharma Ltd. - Phase III, 2014 15 RedHill Biopharma Ltd. - Phase II, 2014 16 RedHill Biopharma Ltd. - Preclinical, 2014 17 RedHill Biopharma Ltd. - Pipeline by Target, 2014 26 RedHill Biopharma Ltd. - Pipeline by Route of Administration, 2014 27 RedHill Biopharma Ltd. - Pipeline by Molecule Type, 2014 28 RedHill Biopharma Ltd. - Pipeline Products by Mechanism of Action, 2014 30 RedHill Biopharma Ltd. - Recent Pipeline Updates, 2014 31
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.